Stock Buy Or Sell - Trxc

: Shareholders at the time of the merger were entitled to receive the $0.35 per share cash payout.

: Leading up to its acquisition, the company reported a Q2 2024 revenue of $2.2 million but sustained a net loss of $25.7 million for the same period. Investment Outlook trxc stock buy or sell

Since the company is now , it is not possible to buy or sell shares on public markets. : Shareholders at the time of the merger

: In March 2021, the company changed its name from TransEnterix to Asensus Surgical to align with its focus on "Performance-Guided Surgery". : In March 2021, the company changed its

: KARL STORZ acquired the company primarily for its Senhance Surgical System and the development of the next-generation LUNA™ System , aiming to integrate these into their global endoscopy portfolio.

: As a result of becoming a private subsidiary of KARL STORZ, the common stock has ceased trading on the NYSE American Exchange. Historical Context (TRXC to ASXC)